Beam Therapeutics Inc.
BEAM-304
phenylketonuria
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for BEAM-304 in phenylketonuria are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The planned Phase 1/2 trial will initially evaluate safety, tolerability, and reduction of blood Phe levels in PKU patients with the R408W mutation, followed thereafter by a base editor for a second mutation, with a goal of establishing cli”